1 The evolution of knowledge on genes associated with human diseases

- 2
- 3 Thomaz Lüscher-Dias¹, Rodrigo Juliani Siqueira Dalmolin^{2,3}, Paulo de Paiva Amaral⁴, Tiago
- 4 Lubiana Alves⁴, Viviane Schuch⁴, Glória Regina Franco¹, Helder I Nakaya^{4,5,6*}.
- 5
- 6 ¹ Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal
- 7 University of Minas Gerais, Belo Horizonte, MG, Brazil;
- 8 ² Bioinformatics Multidisciplinary Environment—BioME, IMD, Federal University of Rio Grande
- 9 do Norte, Natal, RN, Brazil;
- ³ Department of Biochemistry, CB, Federal University of Rio Grande do Norte, Natal, RN, Brazil;
- 11 ⁴ Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences,
- 12 University of São Paulo, São Paulo, Brazil;
- ⁵ Hospital Israelita Albert Einstein, São Paulo, Brazil.
- ⁶ Scientific Platform Pasteur-University of São Paulo, São Paulo, Brazil
- 15
- 16 *Correspondence to: hnakaya@usp.br

17 Abstract

18 Thousands of scientific articles describing genes associated with human diseases are published 19 every week. Computational methods such as text mining and machine learning algorithms are 20 now able to automatically detect these associations. In this study, we used a cognitive 21 computing text-mining application to construct a knowledge network comprised of 3,723 genes 22 and 99 diseases. We then tracked the yearly changes on these networks to analyze how our 23 knowledge has evolved in the past 30 years. Our approach helped to unravel the molecular bases of diseases over time, and to detect shared mechanisms between clinically distinct 24 25 diseases. It also revealed that multi-purpose therapeutic drugs target genes which are 26 commonly associated with several psychiatric, inflammatory, or infectious disorders. By 27 navigating in this knowledge tsunami, we were able to extract relevant biological information 28 and insights about human diseases.

29

30 Keywords: meta-research, evolution of knowledge, genes, human diseases, network analysis

31 Introduction

32 Thousands of scientific articles are published every day, piling up with millions of already 33 published papers (Fortunato et al., 2018). Keeping abreast of scientific significance has become 34 an overwhelming task for researchers in their own fields and in other areas of science. In this 35 scenario, computational methods such as text mining, machine learning, and cognitive 36 computing are helping scientists to summarize published scientific literature. Recently, machine 37 learning approaches have been used to analyze and integrate a variety of biological and 38 medical data (Littmann et al., 2020; Zitnik et al., 2019). These include methods that integrate 39 electronic health records (Rajkomar et al., 2018), capture latent knowledge from the material 40 science literature (Tshitoyan et al., 2019), and discover potential novel drugs to treat psychiatric 41 and neurological disorders using cognitive computing and network medicine analysis of the 42 medical literature (Lüscher Dias et al., 2020).

43 Particularly, the field of molecular biology has seen a remarkable increase in the number 44 of new studies in recent decades. This has resulted in a large number of genes associated with 45 diseases. As a positive consequence of this efflux of genetic knowledge, diseases that were 46 previously not known to have common etiologies are now being connected through their shared 47 alterations in gene expression and interaction patterns, which has opened many potential new 48 roads for clinical advances (Brooks et al., 2014; Carson et al., 2017; Lees et al., 2011; Postma 49 et al., 2011). One significant example of this trend is the association between psychiatric 50 disorders and immune-related diseases (Gibney and Drexhage, 2013; Marrie et al., 2017; Wang 51 et al., 2015).

52 Network medicine (Barabási et al., 2011), a contemporary approach to studying 53 relationships between genes and diseases, has also been made possible because of the large

54 amounts of data on genes and diseases available online. Moreover, knowledge networks, that 55 is, complex graphs that connect concepts according to the established knowledge, can be 56 analyzed under the network medicine framework to produce novel insights from medical 57 knowledge (Bai et al., 2016; Lüscher Dias et al., 2020).


58 In this study, we used IBM Watson for Drug Discovery (WDD; Y. Chen et al., 2016), a 59 cognitive computing text-mining application, to extract known relationships between genes and 60 psychiatric, inflammatory, and infectious diseases from the peer-reviewed literature published 61 between 1990 and 2018. We developed knowledge networks of genes and diseases and 62 monitored the evolution of these relationships yearly. We then quantified and described how 63 genes were connected to each category of disease over this period and how key biological 64 functions unraveled as new genes were added to the network. We also found pairs of diseases from different categories that significantly share genes with each other, indicating underlying 65 66 clinical proximity between diseases that have not been historically related. Lastly, we explored 67 the genes that were common to all psychiatric, inflammatory, or infectious diseases and 68 investigated which drugs target them. By using a network medicine approach, we were able to 69 extract relevant biological information and new insights of genes, pathways, and therapeutic 70 drugs associated with complex human disorders.

71 Results

72 Evolution of knowledge on the molecular bases of human diseases.

73 We used WDD, a cognitive computing text-mining application, to identify connections 74 between genes and diseases in millions of peer-reviewed studies (Y. Chen et al., 2016). For 75 each year from 1990 to 2018, we queried WDD to obtain gene sets related to 99 inflammatory, 76 psychiatric, and infectious diseases (Table S1). WDD detects terms of interest, such as genes 77 and diseases, in scientific texts (e.g., PubMed abstracts and full text journal articles) and finds 78 contextual elements connecting them (e.g., prepositions and verbs). These connections can be 79 extracted from many distinct sources of evidence such as gene expression alterations, genome-80 wide association studies, or protein expression experiments. A confidence score is established 81 for each relationship based on the strength of the detected semantic association and also the 82 number of documents in which the connection is found. However, the type of study from which 83 the association is obtained is not considered for the calculation of the evidence score. Here, we 84 kept only gene-disease relationships with a confidence score equal or higher than 50%, and 85 which were supported by at least 2 studies.

Next, we built yearly disease-disease networks connecting inflammatory, infectious, and psychiatric diseases according to the significance of the genes shared by each pair of diseases (Fig. 1A). These networks were cumulative: the 2018 network (Fig. 1A, rightmost network) displays all connections found in the entire period, while the 2000 network (Fig. 1A, second network from left to right), for instance, contains all connections from 1990 up to that year. The 1990 network (Fig. 1A, leftmost network) depicts the relationships between diseases from the beginning of the literature registries up to 1990.




95 Figure 1. Evolution of knowledge on the molecular bases of human diseases. A. Disease-96 disease knowledge network on infectious, inflammatory, and psychiatric disorders from 1990 to 97 2018. Nodes represent diseases and are proportional to the number of genes associated with 98 each disease in each year. Edge weights are proportional to the significance of gene-sharing 99 between each pair of diseases. Only edges with a p-value < 0.01 are depicted. **B.** Cumulative 100 number of genes associated with each disease category and with all diseases from 1990 to 101 2018. C. Distribution of the number of genes associated with each disease and category in 102 2018. D. Number of new genes added to the network in each category per year. E. Number of 103 new genes added to the network in selected diseases each year. Color code: Green -104 infectious diseases, orange – inflammatory diseases, and blue – psychiatric disorders.

105

106 We then assessed how these relationships evolved over the past three decades (1990-107 2018) and explored the historical trends of the new genes connected to the network during the 108 period (Fig. 1B-E and Table S2). In 1990, only 95 genes were connected in the network (Fig. 109 1B), and no association between psychiatric disorders and inflammatory or infectious diseases 110 could be established through shared genes (Fig. 1A). Accordingly, the overall similarity between 111 diseases (between or within categories) was low in 1990 (Fig. S1). From 1990 to 2010, with the 112 constant increase in the number of genes associated with diseases in all categories, a 113 preliminary approximation between inflammatory and infectious diseases was observed (Fig. 114 1A, second panel, and Fig. S1A). During the next 9 years (2010 to 2018), the new genes added 115 to the network (Fig. 1B) resulted in a strengthening of the connections between infectious and 116 inflammatory diseases, and a fast approximation between psychiatric disorders and the other 117 two categories (Fig. 1A, fourth panel, and Fig. S1A). Meanwhile, the proximity of diseases within

the same categories also increased (Fig. S1B). Inflammatory diseases occupy a central position in the 2018 network (Fig. 1A, fourth panel), which reflects their high between- and withincategory similarities sustained throughout the 30-year period (Fig. S1). Psychiatric and infectious diseases presented the lowest similarity between each other (Figs. 1A and S1).



- 122
- 123

Figure S1. Evolution of knowledge – supplementary results. A and B. Evolution of the mean disease-disease similarity between diseases of different categories (**A**) or within diseases of the same categories (**B**). **C.** Comparison of the total number of papers retrieved from PubMed on diseases of all categories that were connected to less than 100 genes in the 2018 network with that connected to more than 100 genes in 2018. The *p*-value is obtained from the t-test of the mean comparison between the two distributions.

130

In 2018, a total of 3,723 genes were present in the network (Fig. 1B). The number of
genes associated with each disease in the three different categories in 2018 also varied (Fig.
1C). The infectious diseases with the highest number of connected genes in 2018 were hepatitis
B (414 genes), hepatitis C (506 genes), and HIV infection (856 genes; Fig. 1C). However, 55 of

135 63 infectious diseases were connected to less than 100 genes in 2018 (Fig. 1C). The most 136 connected inflammatory diseases were psoriasis (346 genes), systemic lupus erythematosus 137 (393 genes), and arthritis (490 genes; Fig. 1C). In the category of psychiatric disorders, Alzheimer's disease was the most connected (657 genes), followed by schizophrenia (547 138 139 genes) and depression (402 genes; Fig. 1B). The imbalance in the distribution of genes 140 connected to infectious diseases likely reflects a bias in the research interest toward the 141 discovery of genes related to diseases already connected to more genes. In fact, the 2018 142 network showed that the number of scientific papers that mentioned poorly connected diseases 143 (less than 100 genes) is significantly lower than the number of papers published on highly 144 connected diseases (more than 100 genes) (Fig. S1C).

145 Distinct historical trends of discovery were seen for each disease category (Fig. 1D and 146 Table S3). Prominent peaks of gene-association discovery occurred in 1996 for infectious 147 diseases, in 2005 for inflammatory diseases, and in 2013 for psychiatric disorders (Fig. 1C). 148 From 2010 to 2017, the rate of gene discovery in all three categories increased (Fig. 1C). The significant increase in the number of genes associated with infectious diseases observed in 149 150 1996 was mostly driven by 154 new genes associated with HIV infection (Fig. 1D), which 151 corresponded to 50% of the new genes added to the network in that year (Table S3). The triple 152 therapy for HIV using nucleoside reverse-transcriptase inhibitors and protease inhibitors was 153 established in 1996 (Hammer et al., 1996), which likely influenced this outburst of genetic 154 discovery. The 2005 increase in the number of genes associated with inflammatory diseases 155 was mostly related to the new genes connected to psoriasis (41 genes) and systemic lupus 156 erythematosus (33 genes; Fig. 1D), which together corresponded to 20% of the new genes 157 associated with all of the diseases in 2005 (Table S3). The Th₁₇ cell lineage was discovered in

158 2005 (Langrish et al., 2005), a cell type that has since been strongly associated with 159 autoimmune and infectious diseases (Zambrano-Zaragoza et al., 2014). In 2013, a large 160 number of new genes were associated with Parkinson's disease (165 genes Fig. 1D), which 161 corresponded to 17% of the new genes in the network in that year (Table S3). We could not 162 detect any specific scientific landmark in 2013 that could explain this peak. Nevertheless, 163 important genes related to the innate immune response to pathogens and inflammation are 164 among the new genes associated with Parkinson's disease in 2013, such as interleukin 1 beta 165 (IL1B) and the p105 subunit of the nuclear factor kappa B (NFKB1).

166

167 Evolution of disease relationships between categories

168 Next, we investigated the evolution of the similarity between diseases from different categories according to their shared genes (see Methods section). For the top 9 most 169 170 connected diseases of each category in 2018 (i.e., diseases connected to more genes), we 171 detected the diseases from the other two categories with the most significant gene sharing 172 between them and analyzed how these relationships evolved from 1990 to 2018 (Figs. 2, S2, 173 S3, and S4). Alzheimer's disease was the psychiatric disorder with the highest similarity to 174 inflammatory diseases in 2018, including arthritis and systemic lupus erythematosus (Fig. 2A). 175 The relationships between Alzheimer's disease and these disorders grew steadily in 176 significance from 1990 to 2018 (Fig. S2A), which captures the now well-established relevance of 177 inflammatory processes in the pathophysiology of Alzheimer's disease (Newcombe et al., 2018). 178 Surprisingly, fibromyalgia was similar to several psychiatric diseases: depression, anxiety, 179 bipolar disorder, schizophrenia, and Huntington's disease (Figs. 2A and S2). The total number 180 of genes associated with fibromyalgia in 2018 was low (25 genes), but 72% of these (17 genes)

- 181 are also associated with depression. These are genes related to nervous system development,
- 182 such as brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neuropeptide
- 183 Y (NPY), and inflammatory response, including interleukin 6 (IL6), C-X-C motif chemokine
- 184 ligand 8 (CXCL8), and tumor necrosis factor (TNF). In fact, fibromyalgia patients often present
- 185 psychiatric comorbidities such as depression and anxiety (Galvez-Sánchez et al., 2020).





Figure 2. Evolution of disease relationships between categories. A. Disease-disease similarity between diseases of different categories in the 2018 network according to their shared genes. The similarity score was defined as the $-\log_{10}$ pval of the Fisher's exact test result of the gene overlap between each disease pair. Each heatmap represents the similarity score between diseases of two different categories: A. psychiatric versus inflammatory diseases. **B.** psychiatric versus infectious diseases. **C.** inflammatory versus infectious diseases.

193

194 Among infectious diseases, herpes was the most similar disease to autism, 195 schizophrenia, and Huntington's disease and was also among the top 5 most similar infectious 196 diseases to depression, Parkinson's disease, and Alzheimer's disease (Figs. 2B and S3). 197 Herpes infection might be associated with the development of Alzheimer's disease (Harris and Harris, 2015); the typical amyloid- β deposition that occurs in the brain of Alzheimer's disease 198 199 patients could be an innate immunity mechanism to fight herpes virus infections (Eimer et al., 200 2018). Our results indicate that there has been latent evidence of that association since the 201 early 2000s in the scientific literature (Fig. S3A). In the 2005 network, Alzheimer's disease and 202 herpes virus infection shared 14 genes, which represented 58% of the known genes associated 203 with herpes infection at that time.








207 Figure S2. Disease-disease similarity evolution between psychiatric and inflammatory 208 diseases from 1990 to 2018. A-I. Evolution of the similarity between psychiatric disorders and inflammatory diseases: Alzheimer's disease (A), anxiety disorder (B), autism (C), bipolar 209 disorder (D), dementia (E), depression (F), Huntington's disease (G), Parkinson's disease (H), 210 211 and schizophrenia (I). Similarity scores represent the -log₁₀pval of the Fisher's exact test result 212 of the gene overlap between each disease pair in each year from 1990 to 2018.






213

214

Figure S3. Disease-disease similarity evolution between psychiatric and infectious diseases from 1990 to 2018. A–I. Evolution of the similarity between psychiatric disorders and infectious diseases: Alzheimer's disease (A), anxiety disorder (B), autism (C), bipolar disorder (D), dementia (E), depression (F), Huntington's disease (G), Parkinson's disease (H), and schizophrenia (I). Similarity scores represent the –log₁₀pval of the Fisher's exact test result of the gene overlap between each disease pair in each year from 1990 to 2018.

222 Autoimmune inflammatory diseases, such as systemic lupus erythematosus, arthritis, and psoriasis, also showed strong gene sharing with viral infections such as hepatitis B and C, 223 224 respiratory syncytial virus (RSV) infection, influenza, and HIV (Figs. 2C and S4). The 225 association between viral infections and autoimmune diseases is well documented (Getts et al., 226 2013). For instance, the SARS-CoV-2 virus can trigger Guillain-Barré syndrome, a neurological 227 autoimmune disease, in COVID-19 patients (Dalakas, 2020). Dengue patients also present a 228 higher risk of developing autoimmune diseases, such as systemic lupus erythematosus and 229 vasculitis (Li et al., 2018), an association that was also captured in our analysis of the scientific 230 literature since the late 1990s (Fig. S4I).




232

Figure S4. Disease-disease similarity evolution between inflammatory and infectious diseases from 1990 to 2018. A–I. Evolution of the similarity between psychiatric disorders and infectious diseases: age related osteoporosis (A), ankylosing spondylarthritides (B), arthritis (C), chronic ulcerative colitis (D), Crohn's disease (E), psoriasis (F), sarcoidosis (G), scleroderma (H), and systemic lupus erythematosus (I). Similarity scores represent the –log₁₀pval of the Fisher's exact test result of the gene overlap between each disease pair in each year from 1990 to 2018.

241

242 We then examined the number of publications retrieved from PubMed using the topmost 243 similar pairs of diseases from distinct categories as queries (see Methods section; Fig. 3). The 244 goal was to find out whether the gene-sharing similarities between diseases from different 245 categories detected in our networks could also be captured from direct co-occurrence in the 246 general peer-reviewed literature over the 30-year period. For each disease pair, we obtained a 247 ratio between the similarity score of the diseases (i.e., the significance of the gene sharing 248 between them) and the total number of studies retrieved from PubMed that mention both 249 diseases of the pairs together (Table S4). This similarity-to-paper ratio was used to detect 250 potentially understudied pairs of diseases that significantly share genes. Low similarity-to-paper 251 ratio values (Figs. 3A and 3B, light green, and Table S4) represent similar diseases with many 252 papers already published about them or dissimilar disease pairs. An example of such a pair is 253 fibromyalgia and depression. These diseases have significant gene sharing and also hundreds of scientific papers that explore their relationship in the literature (Fig. 3B). Conversely, the 254 255 genetic association between osteoporosis and mycobacterial infection is low and so is the 256 number of papers that investigate these diseases together (Fig. 3B). These cases were 257 considered as examples of a low knowledge gap between the genetic similarity obtained from 258 our network analysis and the established literature coverage of the disease pairs.



259

260

261 Figure 3. Evolution of the knowledge gap between diseases of different categories. A. 262 Number of disease pairs according to the similarity-to-paper ratio index. This index was obtained as a ratio of the similarity score to the total number of papers published for each 263 264 disease pair in 2018. Low similarity-to-paper ratio (<10) is colored in blue; intermediate 265 similarity-to-paper ratio (10 < ratio < 40) is colored in yellow; and high similarity-to-paper ratio 266 (>40) is colored in pink. B. Selected cases of disease pairs with low, intermediate, or high similarity-to-paper ratios depicting the evolution in the number of papers on each pair and the 267 268 evolution of the similarity between them.

269

270 Cases with an intermediate similarity-to-paper ratio (Figs. 3A and 3B, yellow, and Table 271 S4) were considered as cases of moderate knowledge gap (Fig. 3A), which was the case for 272 arthritis and hepatitis B (Fig. 3B). As previously mentioned, several recent studies have 273 explored the association between viral infections and autoimmune diseases (Dalakas, 2020; 274 Getts et al., 2013; Li et al., 2018). In 2018, there were over 250 published papers in which 275 arthritis and hepatitis B were mentioned together (Fig. 3B). Virally mediated arthritis represents 276 ~1% of all arthritis cases, including cases related to hepatitis B infection (Marks and Marks, 277 2016). Scientists have detected the hepatitis B virus in the synovial fluid of rheumatological 278 patients, which could contribute to the pathogenesis of arthritis (Chen et al., 2018). Although 279 these diseases are known to be clinically associated at least since the 1970s (Mirise and 280 Kitridou, 1979), our results show that the knowledge on the gene sharing between them 281 increased rapidly after 2015, which was not followed at the same rate by the number of papers 282 published on the two diseases together. This represents a potential gap to be explored by novel 283 research on the genetic bases of the relationship between arthritis and hepatitis B.

284 Lastly, we considered the disease pairs with strong gene sharing and few studies 285 supporting a direct association as cases of a high knowledge gap (Figs. 3A and 3B, pink, and 286 Table S4). We suggest that these cases might represent potentially underexplored fields of 287 research that deserve further investigation. Surprisingly, the number of papers published until 288 2018 that mentioned psoriasis and malaria together was neglectable (Fig. 3B). These diseases 289 share 31 genes, one-third of the genes associated with psoriasis, and over 10% of the genes 290 associated with malaria in the 2018 network. Hydroxychloroquine, a drug used to treat malaria 291 (Ben-Zvi et al., 2012) and rheumatic diseases, such as arthritis and lupus (Ben-Zvi et al., 2012),


292 can trigger psoriatic lesions (Balak and Hajdarbegovic, 2017). Among a few papers in which 293 malaria and psoriasis are mentioned together, there is a report from 2014 that describes cases 294 of hydroxychloroquine-induced psoriasis in patients undergoing malaria treatment (Gravani et 295 al., 2014). The authors of this study suggest that there should be guidelines for the 296 management of psoriasis patients who are also at risk of malaria (Gravani et al., 2014). Our 297 findings corroborate the need for future studies to investigate the association between these 298 diseases.

299

300 Evolution of biological pathways

301 We performed a gene overrepresentation analysis (ORA) against Reactome pathways 302 with the genes associated with the top 9 most connected diseases in each year from 1990 to 303 2018 (Figs. 4-6 and Table S5). We detected 433 Reactome pathways that presented significant 304 enrichment (p.adjust < 0.01) among the genes of at least one disease (Table S5). Functional 305 enrichment analysis, such as ORA, often yields too many significant pathways, making these 306 results difficult to interpret at the individual pathway level. For this reason, we used a network 307 approach to reduce the complexity of the obtained set of enriched pathways (see Methods 308 section). Briefly, we built a pathway network (Fig. 4) with the significant Reactome pathways 309 obtained from the ORA. We connected these pathways to each other according to the gene 310 sharing between them, similar to what was done in Fig. 1A. We then identified 11 clusters of 311 closely connected pathways in the network and annotated these clusters according to the main 312 biological functions of the pathways within them (Fig. 4 and Table S5). One of the detected 313 clusters grouped several pathways associated with interferon-stimulated genes, interleukins, 314 and antigen presentation (Fig. 4 and Table S5). The pathways in this cluster were significantly

315 enriched among the genes of diseases in all categories, including malaria, HIV infection, 316 arthritis, lupus, depression, and Alzheimer's disease (Fig. 5). The pathways related to 317 interleukin signaling (e.g., "interleukin 10 signaling"), for instance, were among the top enriched 318 pathways associated with depression genes in the 2018 network (Fig. 5 and Table S5). Another 319 cluster of pathways that showed consistent enrichment across all disease categories was NFkB-320 mediated inflammation induced by toll-like receptors (TLRs), T-cell receptors (TCRs), and B-cell receptors (BCRs; Fig. 4). These results illustrate the most recurring theme detected in our 321 322 study: psychiatric, inflammatory, and infectious diseases share common immunological 323 mechanisms that are mostly related to innate immunity and inflammation.




324

325 Figure 4. Reactome term network built from the ORA results of the genes associated with human diseases in 2018. Significant Reactome ORA terms (p.adjust < 0.01) obtained from the 326 327 genes of the top 9 diseases in the 2018 network were connected to each other according to the significance of the gene sharing between them (edge weight). Only terms with a gene sharing 328 329 with a p.adjust < 0.01 were connected. We detected 11 clusters (node colors) of closely related 330 terms using the Louvain clustering algorithm in the R package igraph (Csardi and Nepusz, 331 2006) and compared the enrichment score distribution of the terms in these clusters in each 332 disease category (box plots). Box plots are colored according to the disease categories: green infectious diseases, orange – inflammatory diseases, and light blue – psychiatric disorders. Dots 333

in the box plots represent individual enriched Reactome pathways that belong to each network

335 cluster.

336



337

338

Figure 5. Key biological pathways are enriched among the genes associated with human diseases in 2018. A. ORA networks depicting the enrichment score of Reactome pathways in selected infectious, inflammatory and psychiatric disorders. The networks in A have the same topology of the network in Figure 04. The nodes are colored according to the logarithm of enrichment score (-log₁₀pval) of the terms represented by each node. **B.** ORA enrichment score distribution of the terms in the clusters and diseases from panel A. Box plots are colored according to the category of each disease: green – infectious, orange – inflammatory, and light

blue – psychiatric. Dots in the box plots represent individual Reactome pathways that belong to
the clusters listed in the y axis and that were enriched in each disease.

348

349 Conversely, we found a cluster of closely connected pathways related to 350 neurotransmission that were enriched mostly among the genes of psychiatric disorders (Fig. 4 and Table S5). However, three inflammatory and infectious diseases (hepatitis B, arthritis, and 351 352 HIV infection) presented enrichment for pathways in this cluster (Fig. 5 and Fig. S5). The genes 353 related to these diseases presented enrichment for the pathway "transcriptional regulation 354 MECP2", a member of the neurotransmission cluster. Methyl CpG binding protein 2 (MECP2) is 355 located in the X chromosome, and mutations in this gene are the primary cause of Rett 356 syndrome (Liyanage and Rastegar, 2014). There is no evidence in the scientific literature that there is a link between HIV infection or hepatitis B and Rett syndrome, but recent studies 357 358 indicate a link between this neurodevelopmental disorder and autoimmune diseases, including 359 arthritis (De Felice et al., 2016). Moreover, AIDS patients can develop neurological 360 manifestations similar to those observed in Rett patients, such as cognitive dysfunction and 361 movement disorders (Brew and Garber, 2018). Our results suggest that the similarity between 362 Rett syndrome and autoimmune diseases might also occur for infectious diseases of viral 363 etiology.

364




Figure S5. ORA network analysis of genes associated with inflammatory, infectious, and psychiatric diseases. Enrichment score distribution of the terms in the clusters from Fig. 4 for diseases not depicted in Fig. 5. Box plots illustrate the distribution of the enrichment scores of the Reactome pathways in each cluster.

369

We also detected other clusters of pathways with similar enrichment results between diseases of different categories (Fig. 4). The genes related to arthritis and those related to Alzheimer's disease presented enrichment for pathways related to the extracellular matrix organization, coagulation, and lipoprotein metabolism (Fig. 5). In arthritis, fibroblast-like synoviocytes become hyper-inflammatory and disrupt the extracellular matrix integrity, which leads to the degradation of synovial joint collagen (Nygaard and Firestein, 2020). In Alzheimer's

disease, some extracellular matrix macromolecules seem to promote the production and stabilization of amyloid β , while others act to protect neurons from amyloidosis (Sethi and Zaia, 2017). The pathways in the signal transduction on growth factor stimulation and GPCRmediated signaling clusters were also enriched among the genes of diseases in all categories (Figs. 4, 5, and S5). This result was expected because the genes involved in signal transduction and intracellular signaling are usually shared between cellular pathways and are involved in virtually all biological functions relevant to diseases (Figs. 5 and S5).

383 After determining the major biological functions related to the genes connected to 384 infectious, inflammatory, and psychiatric diseases in the 2018 network, we investigated how this 385 knowledge evolved from 1990 to 2018 (Fig. 6). The pathways related to interferon-stimulated 386 genes, interleukins, and antigen presentation became enriched for the genes associated with inflammatory and infectious diseases already since the early 1990s (Fig. 6). Surprisingly, this 387 388 enrichment appeared earlier for inflammatory diseases, despite the highly relevant role of 389 interferon-stimulated genes and antigen presentation in infectious diseases. Conversely, there 390 was a significant increase in the enrichment of these pathways for the genes related to 391 depression, autism, and schizophrenia since 2010 (Fig. 6). Recently, the specific roles of the 392 immune system in psychiatric diseases begun to be revealed (Chen et al., 2016; de Baumont et 393 al., 2015; Dong et al., 2018; Madore et al., 2016; Yuan et al., 2019). Particularly, neuroglial cells 394 have gained importance as key neuroimmune players in the development of autism (microglia 395 and oligodendrocytes; Scuderi and Verkhratsky, 2020), Alzheimer's disease (microglia; Clayton 396 et al., 2017), and schizophrenia (astrocytes; Gandal et al., 2018). The association of pathways 397 related to apoptosis, senescence, and cell differentiation with psychiatric disorders has also 398 occurred recently, except with Alzheimer's disease, which began early in the period (Fig. 6).

Alzheimer's, Parkinson's, and Huntington's diseases are neurodegenerative conditions in which chronic neuronal death happens in distinct parts of the brain (Dugger and Dickson, 2017). We also found an increasing association in recent years of genes related to autism and depression to cell fate pathways (Fig. 6), showing that these disorders might also have a neurodegenerative component. In fact, apoptosis and cell death in response to stress and inflammation are relevant factors in the pathogenesis of autism (D. Dong et al., 2018) and depression (Leonard, 2018).





Figure 6. Evolution of knowledge on biological pathways. Ridge plots of the enrichment score of selected clusters from the network in Figure 04 for the top 9 diseases in each category from 1990 to 2018. The height of the ridges are proportional to the mean enrichment score (mean log₁₀pval) of the Reactome pathways in each cluster listed in the y axis.

409

410 Evolution of drug target hub genes

411 Lastly, we examined how drugs that are used to treat inflammatory, infectious, and 412 psychiatric diseases target the genes that are shared between the three categories. We found 413 that 345 genes were common to all disease categories (Fig. 7A). Ninety-nine genes were 414 shared only between inflammatory and psychiatric diseases; 259 were common only between psychiatric and infectious diseases; and a total of 409 genes were related exclusively to 415 416 inflammatory and infectious diseases (Fig. 7A). The remaining genes were unique to 417 inflammatory (493 genes), psychiatric (869 genes), and infectious diseases (1,209 genes; Fig. 418 7A).



420 Figure 7. Evolution of drug target hub genes. A. UpSet plot showing the common genes 421 between all categories (hub genes), between two categories exclusively and genes that are 422 unique to each category. B. Number of therapeutic drugs of inflammatory, infectious, and 423 psychiatric diseases that target the top 20 target hub genes according to the comparative 424 toxicogenomics database (CTD). C. Timeline of the association of the top 20 target hub genes 425 to the gene-disease network. The year in which each gene was associated with the first disease 426 of each category is depicted by the circles with distinct colors for each category. D. Number of 427 hub genes targeted by the top 20 drugs that target more hubs according to CTD. E. Drug-gene 428 network depicting the top 20 drugs and that target hub genes. We selected a few drugs and 429 illustrated their molecular structure and diseases for which they are listed as therapeutic 430 according to CTD.

431

432 We used the comparative toxicogenomics database (CTD; Davis et al., 2021) to find 433 drugs that have a therapeutic relationship with the top 9 diseases and the list of genes that 434 these drugs affect (see Methods section). From these lists, we highlight the top 20 most 435 common target genes of the therapeutic drugs listed by CTD (Fig. 7B). Among these genes, IL6, 436 TNF, and interferon gamma (IFNG) were already connected to inflammatory diseases in the 437 1990 network and were gradually related to diseases in the other two categories until 2002 (Fig. 438 7C). Interleukin 1 beta (IL1B), B-cell lymphoma 2 (BCL2), tumor protein P53 (TP53), and 439 CXCL8 also appeared in our networks in the early 1990s and were first connected to 440 inflammatory diseases (Fig. 7C). Eight drug target genes were first connected to psychiatric 441 disorders (Fig. 7C): caspase 3 (CASP3; 1996), prostaglandin-endoperoxide synthase 2 442 (PTGS2; 1997), heme oxygenase 1 (HMOX1; 2000), BCL-2-associated X (BAX) and mitogen-

443 activated protein kinase 1 (MAPK1: 2001), RAC-alpha serine/threonine-protein kinase (AKT1: 444 2003), nuclear factor erythroid 2-related factor 2 (NFE2L2; 2007), and mitogen-activated protein 445 kinase 1 (MAPK3: 2008). The other 5 genes were first connected to infectious diseases (Fig. 7C): NFkB P65 Subunit (RELA; 1996), poly(ADP-Ribose) polymerase 1 (PARP1) and ATP 446 447 binding cassette subfamily B member 1 (ABCB1; 1999), cyclin dependent kinase inhibitor 1A (CDKN1A; 2001), and caspase 8 (CASP8 ; 2010). All top 20 drug target genes were first 448 449 connected to one of the categories until 2010, with the majority of new connections happening 450 in the 1990s (Fig. 7C). These are very well-known genes involved in inflammation (e.g., IL6 and 451 IL1B), innate immunity (e.g., IFNG), apoptosis (e.g., CASP3 and CASP8), cell cycle (e.g., 452 TP53), and other key biological functions that are altered in several diseases.

453 Next, we found the top 20 therapeutic drugs that affect the most hub genes of inflammatory, psychiatric, and infectious diseases (Fig. 7D). Valproic acid, a class I histone 454 455 deacetylase (HDAC) inhibitor (Göttlicher et al., 2001), was the drug that affected the most hub 456 genes, 259 (Fig. 7D). According to CTD, among the diseases we analyzed in this study, valproic acid is a therapeutic drug for anxiety, autism, bipolar disorder, and schizophrenia (Fig. 7E). This 457 458 drug is also an efficient anti-convulsant used to treat epilepsy (Tomson et al., 2016) because it 459 facilitates gamma-aminobutyric acid (GABAergic) neurotransmission (Chateauvieux et al., 460 2010). There is extensive evidence in the literature of the anti-inflammatory effects of valproic 461 acid and its potential use to treat conditions such as spinal cord injury (S. Chen et al., 2018), 462 renal ischemia (Costalonga et al., 2016), and sepsis-induced heart failure (Shi et al., 2019). 463 Valproate was also speculated as a potential repurposing candidate to treat diseases caused by 464 infectious agents, such as COVID-19 (Pitt et al., 2021) and toxoplasmosis (Goodwin et al., 465 2008). HDAC inhibitors promote epigenetic modifications in the genome that induce the

466 expression of genes in many biological functions and cell types (Hull et al., 2016). This could
467 explain valproic acid's versatility and why it ranked first in our analysis.

468 Among the other top 20 drugs, we found molecules that are currently under investigation 469 for repositioning from one disease category to another. Methotrexate (Fig. 7D), which affects 470 141 genes among the 345 hubs, is used to treat several inflammatory diseases, including 471 psoriasis, lupus, and arthritis (Fig. 7E). Recently, a randomized clinical trial revealed a potential for methotrexate to treat positive symptoms in schizophrenia patients (Chaudhry et al., 2020). 472 473 The authors of the trial argue that this effect of methotrexate might be achieved through 474 resetting of systemic regulatory T-cell control of immune signaling, which is also the way this 475 drug is thought to act in autoimmune diseases (Chaudhry et al., 2020). The use of anti-476 inflammatory drugs for the treatment of neuropsychiatric diseases gained traction in recent years (Kohler et al., 2016; Ozben and Ozben, 2019; Pandurangi and Buckley, 2020; Rosenblat 477 478 et al., 2016) influenced by the increasing evidence that these disorders have underlying immune 479 causes, which we have extensively demonstrated in this study. Dexamethasone (Fig. 7D) is a glucocorticoid anti-inflammatory drug listed in CTD as a therapy for arthritis and depression (Fig. 480 481 7E), but it is also used to treat several other inflammatory disorders. Indeed, dexamethasone 482 was one of the few drugs submitted to randomized clinical trials that reduced mortality in 483 COVID-19 patients subjected to invasive ventilation (RECOVERY Collaborative Group, 2021). 484 Several of the other top 20 drugs were also listed in CTD to be used as therapy for diseases of 485 different categories, such as cyclosporine (hepatitis C and psoriasis), indomethacin (Alzheimer's 486 and autoimmune diseases), dronabinol (neuropsychiatric diseases and HIV infection), and 487 quercetin (anxiety and influenza; Fig. 7E).

488

489 Discussion

490 Similar to the exponential increase in the number of published papers seen in the past 491 decades (Fortunato et al., 2018), the number of genes associated with psychiatric, 492 inflammatory, and infectious diseases have also increased significantly in the past 30 years. 493 This rapid growth in knowledge about the genetic underpinnings of these diseases can be 494 directly attributed to at least two historical landmarks: the publication of the human genome in 495 2001 (Lander et al., 2001; Venter et al., 2001) and the advent of high-throughput DNA-496 sequencing technologies (Margulies et al., 2005). Discrete advances in genes associated with 497 specific diseases could also be spotted throughout the period analyzed here. In 1996, the triple 498 therapy for HIV was developed using nucleoside reverse-transcriptase inhibitors and protease 499 inhibitors (Hammer et al., 1996). In the same year, 50% of the new genes added to the 500 knowledge network were connected to HIV infection. In 2005, a peak of novel genes associated 501 with psoriasis and systemic lupus erythematosus was detected. This year also saw the 502 discovery of the Th₁₇ cell lineage (Langrish et al., 2005). The central role of these pro-503 inflammatory cells in the pathogenesis of autoimmune and infectious diseases was later 504 identified (Zambrano-Zaragoza et al., 2014). Indeed, the key genes of the differentiation and 505 maintenance of the Th₁₇ phenotype in CD4⁺ T lymphocytes, such as interleukin 17F (IL17F), interleukin 21 (IL21), the peroxisome proliferator-activated receptor gamma (PPARG), and the 506 fatty acid-binding protein 5 (FABP5), were connected to psoriasis and systemic lupus 507 508 erythematosus in the network in 2005 (Hwang, 2010; Nalbant and Eskier, 2016).

509 One of the advantages of using text mining and network medicine to study the 510 relationships between genes and diseases is the possibility of detecting novel connections from 511 established scientific knowledge. When two diseases share a genetic mechanism, they can also

512 present common clinical or epidemiological characteristics, despite having distinct etiological 513 backgrounds (Barabási et al., 2011). These similarities can inform researchers of potential 514 treatment options (Lüscher Dias et al., 2020). Here, we showed that diseases from 515 inflammatory, psychiatric, and infectious etiologies significantly share genes with each other. 516 This sharing was strong between disease pairs that were well studied together, such as 517 depression and fibromyalgia. Conversely, the gene sharing between psoriasis and malaria could 518 be perceived in our knowledge networks since the 2000s, but the number of papers featuring 519 the two conditions together in PubMed is virtually null. We detected a few such cases, mostly 520 involving neglected infectious diseases, which could explain the knowledge gap. We also found 521 cases of diseases that just recently began to share genes that also lack many publications 522 directly connecting them in the literature. A case in point is autism and RSV. We also found 523 disease pairs, such as dementia and Toxoplasma gondii infection, for which there have been 524 direct associations in the literature since 1990, but that just recently started to share genes in 525 the network. Our results reveal potentially underexplored pathways for future research on the 526 association between diseases of distinct categories and also for the discovery of new genes 527 related to well-studied disease pairs.

The sharing of genes between diseases from distinct categories also reflects in the overlap of biological functions, particularly those related to immunological processes. The genes of several diseases in all categories presented enrichment for Reactome pathways related to the interferon response, cytokines, and NFkB-mediated inflammation. This pattern was detectable in our networks since the early 1990s for inflammatory diseases and gradually appeared for infectious and psychiatric diseases as well. Pathways associated with neurotransmission were almost exclusively enriched among the genes of psychiatric diseases.

Nevertheless, we found enrichment for a neurotransmission-related pathway, "transcriptional regulation by MECP2", among the genes of HIV infection and hepatitis B that could point to a connection between these disorders and Rett syndrome, a neurological condition. Our functional enrichment results also highlighted the relevance of core cellular functions in diseases of all categories, such as signal transduction and the regulation of gene expression by transcription factors.

541 Our network medicine text mining approach also revealed how shared genes between disease categories can signal toward common therapeutic solutions. The findings presented in 542 543 the last section of our study emphasize the relevance of drugs that target shared genes for the 544 treatment of distinct diseases. Our results show that the genes targeted by therapeutic drugs 545 shared by inflammatory, psychiatric, and infectious diseases have been associated with these 546 disorders early in the past 30 years of scientific research. These genes are associated with 547 inflammation, the cell cycle, apoptosis, and central pathways of cellular function. We also 548 demonstrated that well-established and promising cases of repositioning involve drugs that 549 target shared genes between diseases. Future studies should aim to reveal more common 550 molecular mechanisms between these categories of diseases as well as to harness that 551 knowledge for novel drug discovery and repurposing.

In summary, we could apply a machine learning and cognitive computing text-mining strategy using WDD to extract knowledge about genes related to inflammatory, infectious, and psychiatric diseases from the scientific literature and depict how this knowledge evolved during the past 30 years.

556 Methods

557 Knowledge network construction

558 We built knowledge networks containing interactions between diseases and genes using 559 the WDD (Y. Chen et al., 2016). WDD discovers connections between genes and diseases 560 using a natural language processing algorithm that reads full texts from PMC open access journals, patents, and abstracts in the MEDLINE (PubMed) database. A connection is found 561 562 when two terms of interest (e.g., genes and diseases) are detected in the same sentence, 563 separated by a preposition or a verb. These connections can be derived from many sources of 564 evidence, such as gene expression, disease-associated mutations, genome-wide association 565 studies, or protein expression experiments. WDD attributes a confidence score (0-100%) to 566 each association based on the number of documents in which the relation is found and also on the semantic relevance of the link, determined by the natural language processing algorithm. 567

568 We performed independent searches on WDD with 27 inflammatory diseases, 63 569 infectious diseases, and 9 psychiatric and neurological disorders (Table S1) in July 2018. WDD 570 returned lists of genes related to these diseases according to the scientific literature in each 571 year from 1990 to 2018. These associations are cumulative, that is, the genes associated with 572 the diseases in 2018 include all the associations present in the previous year. We only kept 573 connections between genes and diseases supported by a confidence score of at least 50% and 574 2 documents of evidence. Custom R code was used to process, filter, and analyze data and to plot figures. The full code of all analyses and figures in this study is available at 575 576 https://github.com/csbl-usp/evolution of knowledge.

577

578

579 Evolution of knowledge

580 We calculated Fisher's exact test p-value of the gene overlap between each pair of 581 diseases in each year from 1990 to 2018. The total number of genes connected in the network 582 in each year was used as Fisher's exact test universe. For each year, a disease-disease 583 knowledge network was developed using the -log₁₀pval of the Fisher's exact test ("disease-584 disease similarity") as the edge weight for each disease pair. The networks were constructed 585 using the R package *igraph* (Csardi and Nepusz, 2006) and plotted using the package ggraph. 586 We detected new genes in each year by comparing the list of genes of the diseases in one year 587 to the list of genes of the same disease in the previous year. Thus, we obtained a list of new 588 genes that were added to the network in each year from 1991 to 2018. The total number of 589 genes associated with each disease was also calculated for each year. Line, violin, and ridge 590 plots were created to illustrate the results using ggplot2 (Wickham, 2016).

591

592 Evolution of disease relationships between categories

593 For the top 9 diseases of each category that were connected to the most genes in 2018 594 ("top 9 diseases"), we detected the diseases from the other two categories with the most 595 significant gene sharing between them ("disease pairs") and analyzed how these relationships 596 evolved from 1990 to 2018. The disease-disease similarity scores obtained previously were also 597 used in this analysis. We used the MeSH.db R package (Tsuyuzaki et al., 2015) to obtain the 598 MeSH IDs and terms of all 99 diseases. Using the obtained MeSH terms of the diseases in each 599 pair, we used the easyPubMed R package to search for PubMed papers in which both disease 600 MeSHes were found together. We then used an adapted version of the *fetch_pubmed_data* 601 function (see code in GitHub) of the easyPubMed package to retrieve the number of papers that

602 contained the searched MeSH pairs in each year from 1990 to 2018. We used the disease603 disease similarity score and the number of papers in 2018 to calculate a similarity-to-paper ratio
604 for each disease pair as follows:

$similarity.paper.ratio = \frac{dis.dis.similarity}{numberofpapers}$

605 Low similarity-to-paper ratios (<10) were considered as cases of low knowledge gap between 606 the gene sharing and the general scientific interest in the disease pairs. Pairs in this category 607 included those in which the diseases did not share a significant amount of genes or pairs of 608 similar diseases for which there is also a proportional number of papers that cite the two 609 diseases together. Ratios between 10 and 40 were considered as cases of intermediate 610 knowledge gap, that is, the diseases in the pair are similar in the genes they share, but the 611 number of papers on the two diseases together is not proportionally high. High similarity-to-612 paper ratios (>40) were interpreted as cases of a large knowledge gap. The pairs that fell in this 613 category include diseases that share a significant proportion of their genes but that have almost 614 never been studied together, evidenced by the very low number of papers including the two 615 MeSH terms.

616

617 **Evolution of biological pathways**

We used the *enricher* function of the R package *clusterProfiler* (Yu et al., 2012) to perform an ORA against Reactome pathways of the genes associated with the top 9 diseases of each category in each year. We selected the significant Reactome pathways (p.adjust < 0.01) of the top 9 diseases in 2018 and calculated the significance of the gene overlap between these pathways with Fisher's exact test. We considered only the genes of each significant pathway that were also present in the 2018 gene-disease network. By doing this, we limited pathways to

624 cluster according to the genes shared from our data set, not all the genes in the pathways. We 625 then built a pathway network connecting the significant Reactome terms using the -log₁₀pvalue 626 of the Fisher's exact tests as edge weights, similar to what was done for the disease-disease 627 network in Fig. 1A. We detected clusters of pathways in this network using the *cluster_louvain* 628 function (Blondel et al., 2008) of the igraph R package (Csardi and Nepusz, 2006). Edge 629 weights were considered for the cluster detection. We calculated the weighted degree of each 630 pathway in the network using the strength function of the igraph package (Csardi and Nepusz, 631 2006). We manually annotated the detected clusters for their major biological function using the 632 pathways with the highest weighted degree in each cluster as reference. The significance 633 values (-log₁₀pval) of ORA for the pathways in each cluster were used to make box and ridge 634 plots to illustrate the results for each disease in 2018 and how these results changed from 1990 635 to 2018.

636

637 Evolution of drug target hub genes

638 Using the 2018 gene-disease network, we detected the genes common to all three categories of diseases ("hub genes"). We used the R package UpsetR to visualize the number 639 640 of genes shared and exclusive to the disease categories. We downloaded the drug-gene and 641 the drug-disease interaction databases from the CTD (http://ctdbase.org/; Davis et al., 2021). 642 We used the MeSH terms of the 99 diseases to filter the drug-disease database and kept only interactions between drugs and diseases that were listed as "therapeutic" by CTD. These are 643 644 cases of a "chemical that has a known or potential therapeutic role in a disease (e.g., chemical 645 X is used to treat leukemia)", according to the CTD glossary (Davis et al., 2021). We filtered the 646 drug-gene database and kept only the interactions between the therapeutic drugs and the hub

647 genes of our analysis. This final drug-gene list was used to detect the top 20 drugs that target 648 the most hub genes and the top 20 hub genes most targeted by the therapeutic drugs. We 649 visualized these drug-gene interactions in a network built with the R packages *igraph* and 650 plotted with *ggplot2* and *ggraph*. We used the yearly gene-disease networks to detect when the 651 top 20 drug target hub genes were first connected to diseases in each category to build a 652 timeline.

653

654 Competing interests

655 We declare that the authors have no conflicts of interest.

656

657 Data availability

658 The data and code used to produce the analyses and figures in this study are available 659 at https://github.com/csbl-usp/evolution of knowledge.

660

661 Author Contribution

662 Conceptualization, Investigation, Data Curation and Writing: TLD, RJSD, PPA, VS, GRF 663 and HIN. Software Programming, Formal analysis: TLD, VS, TLA. Repository was developed by 664 TLD and TLA. Resources, Writing Review & Editing: TLD, RJSD, PPA, VS, GRF and HIN; 665 Supervision and Funding acquisition: GRF and HIN.

666

667 Funding

668 This work was supported by Brazilian National Council for Scientific and Technological 669 Development (grant numbers 313662/2017-7); the São Paulo Research Foundation (grant

670 numbers 2018/14933-2).

672 References

673	Bai T, Gong L, Wang Ye, Wang Yan, Kulikowski CA, Huang L. 2016. A method for exploring
674	implicit concept relatedness in biomedical knowledge network. BMC Bioinformatics 17
675	Suppl 9:265. doi:10.1186/s12859-016-1131-5
676	Balak DM, Hajdarbegovic E. 2017. Drug-induced psoriasis: clinical perspectives. <i>Psoriasis</i>
677	(Auckl) 7 :87–94. doi:10.2147/PTT.S126727
678	Barabási A-L, Gulbahce N, Loscalzo J. 2011. Network medicine: a network-based approach to
679	human disease. Nat Rev Genet 12 :56–68. doi:10.1038/nrg2918
680	Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. 2012. Hydroxychloroquine: from malaria to
681	autoimmunity. <i>Clin Rev Allergy Immunol</i> 42 :145–153. doi:10.1007/s12016-010-8243-x
682	Blondel VD, Guillaume J-L, Lambiotte R, Lefebvre E. 2008. Fast unfolding of communities in
683	large networks. J Stat Mech 2008 :P10008. doi:10.1088/1742-5468/2008/10/P10008
684	Brew BJ, Garber JY. 2018. Neurologic sequelae of primary HIV infection. <i>Handb Clin Neurol</i>
685 686	152 :65–74. doi:10.1016/B978-0-444-63849-6.00006-2
686 687	Brooks PJ, Tagle DA, Groft S. 2014. Expanding rare disease drug trials based on shared
687 688	molecular etiology. <i>Nat Biotechnol</i> 32 :515–518. doi:10.1038/nbt.2924
688 680	Carson MB, Liu C, Lu Y, Jia C, Lu H. 2017. A disease similarity matrix based on the uniqueness
689 600	of shared genes. <i>BMC Med Genomics</i> 10 :26. doi:10.1186/s12920-017-0265-2
690	Chateauvieux S, Morceau F, Dicato M, Diederich M. 2010. Molecular and therapeutic potential
691	and toxicity of valproic acid. <i>J Biomed Biotechnol</i> 2010 . doi:10.1155/2010/479364
692	Chaudhry IB, Husain MO, Khoso AB, Husain MI, Buch MH, Kiran T, Fu B, Bassett P, Qurashi I,
693	Ur Rahman R, Baig S, Kazmi A, Corsi-Zuelli F, Haddad PM, Deakin B, Husain N. 2020. A
694	randomised clinical trial of methotrexate points to possible efficacy and adaptive immune
695	dysfunction in psychosis. <i>Transl Psychiatry</i> 10 :415. doi:10.1038/s41398-020-01095-8
696	Chen H, Liu S, Ji L, Wu T, Ji Y, Zhou Y, Zheng M, Zhang M, Xu W, Huang G. 2016. Folic acid
697	supplementation mitigates alzheimer's disease by reducing inflammation: A randomized
698	controlled trial. <i>Mediators Inflamm</i> 2016 :5912146. doi:10.1155/2016/5912146
699	Chen S, Ye J, Chen X, Shi J, Wu W, Lin Wenping, Lin Weibin, Li Y, Fu H, Li S. 2018. Valproic
700	acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-κB
701	pathway dependent of HDAC3. J Neuroinflammation 15:150. doi:10.1186/s12974-018-
702	1193-6
703	Chen Y, Elenee Argentinis JD, Weber G. 2016. IBM watson: how cognitive computing can be
704	applied to big data challenges in life sciences research. Clin Ther 38 :688–701.
705	doi:10.1016/j.clinthera.2015.12.001
706	Chen Y-L, Jing J, Mo Y-Q, Ma J-D, Yang L-J, Chen L-F, Zhang X, Yan T, Zheng D-H, Pessler F,
707	Dai L. 2018. Presence of hepatitis B virus in synovium and its clinical significance in
708	rheumatoid arthritis. Arthritis Res Ther 20:130. doi:10.1186/s13075-018-1623-y
709	Clayton KA, Van Enoo AA, Ikezu T. 2017. Alzheimer's disease: the role of microglia in brain
710	homeostasis and proteopathy. Front Neurosci 11:680. doi:10.3389/fnins.2017.00680
711	Costalonga EC, Silva FMO, Noronha IL. 2016. Valproic Acid Prevents Renal Dysfunction and

712 Inflammation in the Ischemia-Reperfusion Injury Model. Biomed Res Int 2016:5985903. 713 doi:10.1155/2016/5985903 714 Csardi G. Nepusz T. 2006. The igraph software package for complex network research. 715 InterJournal Complex Systems:1695. 716 Dalakas MC. 2020. Guillain-Barré syndrome: The first documented COVID-19-triggered 717 autoimmune neurologic disease: More to come with myositis in the offing. Neurol 718 Neuroimmunol Neuroinflamm 7. doi:10.1212/NXI.000000000000781 719 Davis AP, Grondin CJ, Johnson RJ, Sciaky D, Wiegers J, Wiegers TC, Mattingly CJ. 2021. 720 Comparative Toxicogenomics Database (CTD): update 2021. Nucleic Acids Res 721 49:D1138–D1143. doi:10.1093/nar/gkaa891 722 de Baumont A, Maschietto M, Lima L, Carraro DM, Olivieri EH, Fiorini A, Barreta LAN, Palha 723 JA, Belmonte-de-Abreu P, Moreira Filho CA, Brentani H. 2015. Innate immune response is 724 differentially dysregulated between bipolar disease and schizophrenia. Schizophr Res 161:215-221. doi:10.1016/j.schres.2014.10.055 725 726 De Felice C, Leoncini S, Signorini C, Cortelazzo A, Rovero P, Durand T, Ciccoli L, Papini AM, Hayek J. 2016. Rett syndrome: An autoimmune disease? Autoimmun Rev 15:411-416. 727 728 doi:10.1016/j.autrev.2016.01.011 Dong D, Zielke HR, Yeh D, Yang P. 2018. Cellular stress and apoptosis contribute to the 729 pathogenesis of autism spectrum disorder. Autism Res 11:1076-1090. 730 731 doi:10.1002/aur.1966 732 Dong Y, Lagarde J, Xicota L, Corne H, Chantran Y, Chaigneau T, Crestani B, Bottlaender M, 733 Potier M-C, Aucouturier P, Dorothée G, Sarazin M, Elbim C. 2018. Neutrophil 734 hyperactivation correlates with Alzheimer's disease progression. Ann Neurol 83:387-405. 735 doi:10.1002/ana.25159 736 Dugger BN, Dickson DW. 2017. Pathology of neurodegenerative diseases. Cold Spring Harb 737 Perspect Biol 9. doi:10.1101/cshperspect.a028035 Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, Rodriguez AS, Mitchell T, Washicosky 738 739 KJ, György B, Breakefield XO, Tanzi RE, Moir RD. 2018. Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. Neuron 740 741 100:1527–1532. doi:10.1016/j.neuron.2018.11.043 742 Fortunato S, Bergstrom CT, Börner K, Evans JA, Helbing D, Milojević S, Petersen AM, Radicchi 743 F, Sinatra R, Uzzi B, Vespignani A, Waltman L, Wang D, Barabási A-L. 2018. Science of 744 science. Science 359. doi:10.1126/science.aao0185 745 Galvez-Sánchez CM, Montoro CI, Duschek S, Reves Del Paso GA. 2020. Depression and traitanxiety mediate the influence of clinical pain on health-related quality of life in fibromyalgia. 746 747 J Affect Disord 265:486-495. doi:10.1016/j.jad.2020.01.129 748 Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, Won H, van Bakel H, Varghese M, Wang Y, Shieh AW, Haney J, Parhami S, Belmont J, Kim M, Moran Losada P, 749 750 Khan Z, Mleczko J, Xia Y, Dai R, Geschwind DH. 2018. Transcriptome-wide isoform-level 751 dysregulation in ASD, schizophrenia, and bipolar disorder. Science 362.

752 doi:10.1126/science.aat8127

753	Getts DR, Chastain EML, Terry RL, Miller SD. 2013. Virus infection, antiviral immunity, and
754	autoimmunity. Immunol Rev 255:197–209. doi:10.1111/imr.12091
755	Gibney SM, Drexhage HA. 2013. Evidence for a dysregulated immune system in the etiology of
756	psychiatric disorders. J Neuroimmune Pharmacol 8:900-920. doi:10.1007/s11481-013-
757	9462-8
758	Goodwin DG, Strobl J, Mitchell SM, Zajac AM, Lindsay DS. 2008. Evaluation of the mood-
759	stabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity
760	against tissue cysts in mice. J Parasitol 94:555–557. doi:10.1645/GE-1331.1
761	Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F,
762	Nervi C, Pelicci PG, Heinzel T. 2001. Valproic acid defines a novel class of HDAC inhibitors
763	inducing differentiation of transformed cells. EMBO J 20:6969–6978.
764	doi:10.1093/emboj/20.24.6969
765	Gravani A, Gaitanis G, Zioga A, Bassukas ID. 2014. Synthetic antimalarial drugs and the
766	triggering of psoriasis - do we need disease-specific guidelines for the management of
767	patients with psoriasis at risk of malaria? Int J Dermatol 53:327-330. doi:10.1111/ijd.12231
768	Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry
769	WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. 1996. A trial comparing
770	nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell
771	counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study
772	Team. N Engl J Med 335:1081–1090. doi:10.1056/NEJM199610103351501
773	Harris SA, Harris EA. 2015. Herpes simplex virus type 1 and other pathogens are key causative
774	factors in sporadic alzheimer's disease. J Alzheimers Dis 48:319-353. doi:10.3233/JAD-
775	142853
776	Hull EE, Montgomery MR, Leyva KJ. 2016. HDAC inhibitors as epigenetic regulators of the
777	immune system: impacts on cancer therapy and inflammatory diseases. Biomed Res Int
778	2016 :8797206. doi:10.1155/2016/8797206
779	Hwang ES. 2010. Transcriptional regulation of T helper 17 cell differentiation. Yonsei Med J
780	51 :484–491. doi:10.3349/ymj.2010.51.4.484
781	Kohler O, Krogh J, Mors O, Benros ME. 2016. Inflammation in Depression and the Potential for
782	Anti-Inflammatory Treatment. Curr Neuropharmacol 14:732–742.
783	doi:10.2174/1570159x14666151208113700
784	Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M,
785	FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J,
786	LeVine R, McEwan P, McKernan K, et al. 2001. Initial sequencing and analysis of the
787	human genome. Nature 409 :860–921. doi:10.1038/35057062
788	Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T,
789	Kastelein RA, Cua DJ. 2005. IL-23 drives a pathogenic T cell population that induces
790	autoimmune inflammation. J Exp Med 201:233–240. doi:10.1084/jem.20041257
791	Lees CW, Barrett JC, Parkes M, Satsangi J. 2011. New IBD genetics: common pathways with

792 other diseases. Gut 60:1739-1753. doi:10.1136/gut.2009.199679 793 Leonard BE. 2018. Inflammation and depression: a causal or coincidental link to the 794 pathophysiology? Acta Neuropsychiatr 30:1–16. doi:10.1017/neu.2016.69 Li H-M, Huang Y-K, Su Y-C, Kao C-H. 2018. Increased risk of autoimmune diseases in dengue 795 796 patients: A population-based cohort study. J Infect 77:212-219. 797 doi:10.1016/j.jinf.2018.03.014 798 Littmann M, Selig K, Cohen-Lavi L, Frank Y, Hönigschmid P, Kataka E, Mösch A, Qian K, Ron 799 A, Schmid S, Sorbie A, Szlak L, Dagan-Wiener A, Ben-Tal N, Niv MY, Razansky D, 800 Schuller BW, Ankerst D, Hertz T, Rost B. 2020. Validity of machine learning in biology and 801 medicine increased through collaborations across fields of expertise. Nat Mach Intell. doi:10.1038/s42256-019-0139-8 802 Livanage VRB, Rastegar M. 2014. Rett syndrome and MeCP2. Neuromolecular Med 16:231-803 804 264. doi:10.1007/s12017-014-8295-9 805 Lüscher Dias T, Schuch V, Beltrão-Braga PCB, Martins-de-Souza D, Brentani HP, Franco GR, Nakaya HI. 2020. Drug repositioning for psychiatric and neurological disorders through a 806 network medicine approach. Transl Psychiatry 10:141. doi:10.1038/s41398-020-0827-5 807 808 Madore C, Levrolle Q, Lacabanne C, Benmamar-Badel A, Joffre C, Nadjar A, Lavé S. 2016. 809 Neuroinflammation in autism: plausible role of maternal inflammation, dietary omega 3, and microbiota. Neural Plast 2016:3597209. doi:10.1155/2016/3597209 810 Margulies M, Egholm M, Altman WE, Attiva S, Bader JS, Bemben LA, Berka J, Braverman MS, 811 812 Chen Y-J, Chen Z, Dewell SB, Du L, Fierro JM, Gomes XV, Godwin BC, He W, Helgesen 813 S, Ho CH, Irzyk GP, Jando SC, Rothberg JM. 2005. Genome sequencing in 814 microfabricated high-density picolitre reactors. Nature 437:376-380. doi:10.1038/nature03959 815 816 Marks M, Marks JL. 2016. Viral arthritis. Clin Med 16:129-134. doi:10.7861/clinmedicine.16-2-817 129 Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, 818 819 El-Gabalawy R, Katz A, Fisk JD, Bernstein CN, CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. 820 821 2017. Increased incidence of psychiatric disorders in immune-mediated inflammatory 822 disease. J Psychosom Res 101:17-23. doi:10.1016/j.jpsychores.2017.07.015 823 Mirise RT, Kitridou RC. 1979. Arthritis and hepatitis. West J Med 130:12-17. Nalbant A, Eskier D. 2016. Genes associated with T helper 17 cell differentiation and function. 824 825 Front Biosci (Elite Ed) 8:427-435. doi:10.2741/e777 Newcombe EA, Camats-Perna J, Silva ML, Valmas N, Huat TJ, Medeiros R. 2018. 826 827 Inflammation: the link between comorbidities, genetics, and Alzheimer's disease. J Neuroinflammation 15:276. doi:10.1186/s12974-018-1313-3 828 829 Nygaard G, Firestein GS. 2020. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol 16:316-333. 830 831 doi:10.1038/s41584-020-0413-5

Ozben T, Ozben S. 2019. Neuro-inflammation and anti-inflammatory treatment options for
 Alzheimer's disease. *Clin Biochem* **72**:87–89. doi:10.1016/j.clinbiochem.2019.04.001

Pandurangi AK, Buckley PF. 2020. Inflammation, Antipsychotic Drugs, and Evidence for
 Effectiveness of Anti-inflammatory Agents in Schizophrenia. *Curr Top Behav Neurosci*

44:227–244. doi:10.1007/7854_2019_91

- Pitt B, Sutton NR, Wang Z, Goonewardena SN, Holinstat M. 2021. Potential repurposing of the
 HDAC inhibitor valproic acid for patients with COVID-19. *Eur J Pharmacol* 898:173988.
 doi:10.1016/j.ejphar.2021.173988
- Postma DS, Kerkhof M, Boezen HM, Koppelman GH. 2011. Asthma and chronic obstructive
 pulmonary disease: common genes, common environments? *Am J Respir Crit Care Med*183:1588–1594. doi:10.1164/rccm.201011-1796PP
- 843 Rajkomar A, Oren E, Chen K, Dai AM, Hajaj N, Hardt M, Liu PJ, Liu X, Marcus J, Sun M,
- 844Sundberg P, Yee H, Zhang K, Zhang Y, Flores G, Duggan GE, Irvine J, Le Q, Litsch K,845Mossin A, Dean J. 2018. Scalable and accurate deep learning with electronic health
- 846 records. *npj Digital Med* **1**:18. doi:10.1038/s41746-018-0029-1
- 847 RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell
- L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick
 D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Landray MJ. 2021. Dexamethasone in
 Hospitalized Patients with Covid-19. *N Engl J Med* 384:693–704.
- 851 doi:10.1056/NEJMoa2021436
- Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, Mansur RB, Brietzke E,
 Goldstein BI, McIntyre RS. 2016. Anti-inflammatory agents in the treatment of bipolar
 depression: a systematic review and meta-analysis. *Bipolar Disord* 18:89–101.
- 855 doi:10.1111/bdi.12373
- Scuderi C, Verkhratsky A. 2020. The role of neuroglia in autism spectrum disorders. *Prog Mol Biol Transl Sci* 173:301–330. doi:10.1016/bs.pmbts.2020.04.011
- Sethi MK, Zaia J. 2017. Extracellular matrix proteomics in schizophrenia and Alzheimer's
 disease. Anal Bioanal Chem 409:379–394. doi:10.1007/s00216-016-9900-6
- Shi X, Liu Y, Zhang D, Xiao D. 2019. Valproic acid attenuates sepsis-induced myocardial
 dysfunction in rats by accelerating autophagy through the PTEN/AKT/mTOR pathway. *Life Sci* 232:116613. doi:10.1016/j.lfs.2019.116613
- Tomson T, Battino D, Perucca E. 2016. The remarkable story of valproic acid. *Lancet Neurol* **15**:141. doi:10.1016/S1474-4422(15)00398-1
- Tshitoyan V, Dagdelen J, Weston L, Dunn A, Rong Z, Kononova O, Persson KA, Ceder G, Jain
 A. 2019. Unsupervised word embeddings capture latent knowledge from materials science
 literature. *Nature* 571:95–98. doi:10.1038/s41586-019-1335-8
- 868 Tsuyuzaki K, Morota G, Ishii M, Nakazato T, Miyazaki S, Nikaido I. 2015. MeSH ORA
- framework: R/Bioconductor packages to support MeSH over-representation analysis. *BMC Bioinformatics* 16:45. doi:10.1186/s12859-015-0453-z
- 871 Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans

- CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huson DH, Wortman JR, Zhang Q,
 Kodira CD, Zheng XH, Chen L, Skupski M, et al. 2001. The sequence of the human
 genome. *Science* 291:1304–1351. doi:10.1126/science.1058040
- Wang Q, Yang C, Gelernter J, Zhao H. 2015. Pervasive pleiotropy between psychiatric
 disorders and immune disorders revealed by integrative analysis of multiple GWAS. *Hum Genet* 134:1195–1209. doi:10.1007/s00439-015-1596-8
- Wickham H. 2016. ggplot2 Elegant Graphics for Data Analysis, 2nd ed. Cham: Springer
 International Publishing. doi:10.1007/978-3-319-24277-4
- Yuan N, Chen Y, Xia Y, Dai J, Liu C. 2019. Inflammation-related biomarkers in major psychiatric
 disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta analyses. *Transl Psychiatry* **9**:233. doi:10.1038/s41398-019-0570-y
- 883 Yu G, Wang L-G, Han Y, He Q-Y. 2012. clusterProfiler: an R package for comparing biological 884 themes among gene clusters. *OMICS* **16**:284–287. doi:10.1089/omi.2011.0118
- 885 Zambrano-Zaragoza JF, Romo-Martínez EJ, Durán-Avelar M de J, García-Magallanes N,
- Vibanco-Pérez N. 2014. Th17 cells in autoimmune and infectious diseases. *Int J Inflam*2014:651503. doi:10.1155/2014/651503
- Zitnik M, Nguyen F, Wang B, Leskovec J, Goldenberg A, Hoffman MM. 2019. Machine learning
- for integrating data in biology and medicine: principles, practice, and opportunities. *Inf Fusion* <u>50:71–91. doi:10.1016/j.inffus.2018.09.012</u>